Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 164

Results For "US"

8882 News Found

Sustaining growth momentum is key for Navin Fluorine: ICICI Securities
News | October 31, 2022

Sustaining growth momentum is key for Navin Fluorine: ICICI Securities

NFIL’s ambition is to reach revenues of US$100mn from CDMO by FY25.


USFDA issues Form-483 for Lupin's Nagpur Unit-2
Drug Approval | October 31, 2022

USFDA issues Form-483 for Lupin's Nagpur Unit-2

The company is committed to addressing the observations at the earliest, and gaining approval for injectable manufacturing for the US


USFDA determines inspection classification of Jubilant Pharmova's Roorkee facility
News | October 31, 2022

USFDA determines inspection classification of Jubilant Pharmova's Roorkee facility

The company currently supplies one product to the US market that contributes low- single digit revenue to Jubilant Pharmova revenue


Zydus receives final approval from USFDA for Acetaminophen injection
Drug Approval | October 30, 2022

Zydus receives final approval from USFDA for Acetaminophen injection

Acetaminophen injection had annual sales of US $72 million in the United States according to IQVIA data


USFDA issues Form 483 for Parawada unit of Laurus Labs
Drug Approval | October 30, 2022

USFDA issues Form 483 for Parawada unit of Laurus Labs

The observation is procedural in nature and the company will address the observation within stipulated timelines.


Zydus gets USFDA’s approval for Ketorolac Tromethamine Tablets
Drug Approval | October 27, 2022

Zydus gets USFDA’s approval for Ketorolac Tromethamine Tablets

Ketorolac Tromethamine Tablets are indicated to relieve moderately severe pain, usually after surgery.


USFDA Issues a CRL for the Biologics License Application for Insulin Aspart
Drug Approval | October 27, 2022

USFDA Issues a CRL for the Biologics License Application for Insulin Aspart

The CRL did not identify any outstanding scientific issues with the product.


Laurus Labs planning Rs. 2,000 Cr Capex
News | October 27, 2022

Laurus Labs planning Rs. 2,000 Cr Capex

On the Capex front, the company has invested Rs. 416 crore in the first half and it is broadly in line with our guidance for the two years around Rs. 2,000 crore across all the subsidiaries and divisions


Zydus receives final approval from USFDA for Micafungin for Injection
Drug Approval | October 26, 2022

Zydus receives final approval from USFDA for Micafungin for Injection

Micafungin for Injection had annual sales of US $99 million in the United States according to IQVIA data


Healthcare firms discover ways to use VR to treat neurological diseases, says GlobalData
Digitisation | October 26, 2022

Healthcare firms discover ways to use VR to treat neurological diseases, says GlobalData

The global VR market to grow at a compound annual growth rate of 13% from $7 billion in 2018 to $28 billion in 2030.